Please use this identifier to cite or link to this item:
Title: Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
Filiation: Hospital Universitario Príncipe de Asturias
Issue Date: Jan-2022
Publisher: BMJ
Citation: Heart.2022 Jan;(108)2:130-136
Abstract: Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.
PMID: 34611045
Rights: info:eu-repo/semantics/openAccess
ISSN: 1355-6037
Appears in Collections:Hospitales > H. U. Príncipe de Asturias > Artículos

Files in This Item:
File Description SizeFormat 
34611045.pdfAntiplatelet therapy and outcome in COVID-19701.49 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons